
US-based Deciphera Pharmaceuticals develops kinase inhibitor treatments for various cancers globally.
Deciphera Pharmaceuticals, founded in Waltham, United States, is a biotechnology company dedicated to discovering and developing kinase inhibitor treatments for various types of cancer. Their core mission is to defeat cancer and improve the lives of patients globally. The company focuses on treating gastrointestinal stromal tumors, advanced systemic mastocytosis, gliomas, and other solid tumors. Deciphera's product pipeline reflects their commitment to innovative cancer therapies.
Notable figures affiliated with Deciphera Pharmaceuticals include its team of experienced scientists and executives who have significantly contributed to oncology research. The company has attracted substantial investment from leading biotech investors. Key achievements include the development and approval of several kinase inhibitors that have shown promise in clinical trials. Deciphera's impact is evident in its contributions to cancer treatment advancements and its ongoing efforts to support patient communities worldwide.

Blueprint Medicines

Karyopharm Therapeutics
karyopharm.com

BeOne Medicines
beigene.com

G1 Therapeutics
g1therapeutics.com

Incyte
incyte.com

Kiniksa Pharmaceuticals
kiniksa.com

Verastem

Revolution Medicines
revmed.com

Traws Pharma

Clovis Oncology

Accelerated Pharma

ImageneBio
ikenaoncology.com

Syndax Pharmaceuticals
syndax.com

Seagen
seagen.com

Foundation Medicine
Companies similar to Deciphera Pharmaceuticals include Blueprint Medicines, Karyopharm Therapeutics, BeOne Medicines and G1 Therapeutics.
Deciphera Pharmaceuticals was founded in 2003.
Deciphera Pharmaceuticals' headquarters is located in Waltham, MA, US.
Deciphera Pharmaceuticals' most recent funding round was for $125M (USD) in January 2023.
As of Jan 19, 2023, Deciphera Pharmaceuticals has raised a total of $1B (USD).